Pondy Oxides & Chemicals Limited has received monitoring agency reports from CARE Ratings Limited confirming the complete utilisation of proceeds from two separate capital-raising exercises — a Qualified Institutional Placement (QIP) aggregating to Rs. 174.99 crore and a Preferential Issue aggregating to Rs. 132.50 crore — both for the quarter ended March 31, 2026. The QIP report was submitted pursuant to Regulation 32 of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, read with Regulation 173A of SEBI (Issue of Capital & Disclosure Requirements) Regulations, 2018, while the Preferential Issue report was submitted under Regulation 32 read with Regulation 162A of the same SEBI (Issue of Capital & Disclosure Requirements) Regulations, 2018. Both reports have been uploaded on the company's website and confirm nil deviation from the objects stated in the respective offer documents.

Issue Overview

The QIP had a valid offer period from December 17, 2024, to December 20, 2024, comprising equity shares issued by Pondy Oxides & Chemicals, a company operating in the non-ferrous metals sector. The Preferential Issue had a valid offer period from February 16, 2024, to February 25, 2024, and comprised equity shares and warrants. The monitoring agency agreement for the QIP was dated December 07, 2024, while that for the Preferential Issue was dated January 24, 2024. The following table summarises the key issue details for both disclosures:

Utilisation of QIP Proceeds

The company raised Rs. 174.99 crore through the issuance of 20,34,883 equity shares at a price of Rs. 860 per share under the QIP. After deducting issue expenses of Rs. 6.03 crore, the net proceeds of Rs. 168.96 crore were allocated towards specific objects. The following table details the cumulative utilisation of QIP proceeds as at the end of the quarter:

Quarterly Deployment Breakdown — QIP

Of the total Rs. 174.99 crore, Rs. 160.83 crore had already been utilised at the beginning of the quarter, with Rs. 14.16 crore deployed during the quarter to complete the capital expenditure for the recycling and processing unit in Tiruvallur, Tamil Nadu. CARE Ratings noted that Rs. 0.23 crore was spent directly from the monitoring account towards CAPEX, while Rs. 13.93 crore was utilised from the cash credit (CC) account and subsequently transferred from the monitoring account to the CC account. The following table presents the quarter-wise movement of QIP utilisation:

Utilisation of Preferential Issue Proceeds

Under the Preferential Issue, the company raised proceeds through two instruments — equity shares and warrants. The equity issue was undersubscribed to the extent of 19,724 shares, resulting in the company receiving Rs. 50.00 crore as against the originally envisaged Rs. 51.00 crore; the General Corporate Purpose allocation was accordingly revised from Rs. 11.00 crore to Rs. 10.00 crore. The warrants component raised Rs. 82.50 crore, with Rs. 12.69 crore deployed during the quarter towards the purchase of fixed assets including plant and machinery. CARE Ratings noted that Rs. 0.63 crore was transferred towards vendor accounts from the monitoring account and Rs. 12.06 crore was utilised from the CC account and then transferred from the monitoring account to the CC account.

The following tables detail the utilisation of proceeds from the preferential issue of equity shares and warrants respectively:

Preferential Issue — Equity Shares

Preferential Issue — Warrants

Implementation Timeline and Compliance

All objects under both the QIP and the Preferential Issue were completed within the stipulated deadlines, with no delays reported. Under the QIP, working capital requirements and general corporate purposes were completed by March 31, 2025, while capital expenditure for the recycling and processing unit in Tiruvallur, Tamil Nadu, was completed by March 31, 2026. Under the Preferential Issue of equity shares, purchase of fixed assets was completed as on June 30, 2024, while working capital deployment and general corporate purposes were completed as on March 31, 2024. Under the Preferential Issue of warrants, purchase of fixed assets was completed as on March 31, 2026, while working capital deployment and general corporate purposes were completed as on September 30, 2025. The following table summarises the completion timeline for both issues:

Monitoring Agency Declaration

CARE Ratings Limited, in its capacity as monitoring agency for both issues, declared that the reports provide an objective view of the utilisation of issue proceeds based on information provided by the issuer and sources believed to be accurate and reliable. The agency noted that it does not perform an audit and undertakes no independent verification of information, certifications, or statements received. Since all proceeds under both issues were fully utilised as on March 31, 2026, the deployment of unutilised proceeds was reported as not applicable for both. All government and statutory approvals related to the objects had been obtained, and the means of finance for the disclosed objects remained unchanged. Both reports were prepared based on bank statements, a Chartered Accountant certificate from L. Mukundan & Associates dated May 04, 2026, and management confirmation. The reports were signed by Ali Monish PE, Assistant Director at CARE Ratings Limited, and submitted to the Board of Directors of Pondy Oxides & Chemicals on May 7, 2026.

Pondy Oxides & Chemicals has notified the stock exchanges of an upcoming Board of Directors meeting, pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting is scheduled to be held on Tuesday, 26th May 2026 at 03:00 PM. The disclosure was made on 8th May 2026 and was addressed to both the National Stock Exchange of India Ltd and BSE Limited.

Board Meeting Agenda

The board meeting has been convened to address key financial and corporate matters pertaining to the financial year 2025-26. The following items are on the agenda:

Key Agenda Items

The primary items proposed to be discussed at the meeting include:

• Approval of Audited Financials: Consideration and approval of audited standalone and consolidated financial statements for the financial year 2025-26 and for the quarter ended 31st March 2026.
• Dividend Recommendation: Consideration and recommendation of dividend, if any, for the financial year 2025-26.
• Other Business: Any other subject as may arise during the course of the meeting.

The intimation was signed by K Kumaravel, Director Finance and Company Secretary of Pondy Oxides & Chemicals, confirming the regulatory disclosure under the applicable SEBI listing regulations.